On February 23, 2025, Persatuan Insurans Am Malaysia (PIAM), the Malaysian Takaful Association (MTA), and the Life Insurance Association Malaysia (LIAM) jointly released an electronic document titled Price Ranges for Common Private Healthcare Services in Malaysia.
The publication, available via the three assurance portals, is described as an informational reference developed from an analysis of historical treatment cost demographics.
On February 23, 2025, Persatuan Insurans Am Malaysia (PIAM), the Malaysian Takaful Association (MTA), and the Life Insurance Association Malaysia (LIAM) jointly released an electronic document titled Price Ranges for Common Private Healthcare Services in Malaysia.
The publication, available via the three assurance portals, is described as an informational reference developed from an analysis of historical treatment cost demographics.
The stated objective of the document is to enhance transparency and support informed health care decision-making by providing the public with a general understanding of price ranges charged by private health care providers.
The publication explicitly clarifies that the figures presented do not reflect regulated or fixed pricing and that actual charges may vary based on medical complexity, provider practices, and individual patient circumstances. A clear disclaimer reiterates that the information is provided solely for general reference.
While the initiative reflects an industry effort toward cost transparency, its practical value and policy relevance warrant closer examination.
Clarity Of Objective And Intended Impact
The document claims to be primarily targeted at policyholders, with the aim of creating value by improving transparency. However, the mechanism through which value is created remains insufficiently articulated.
In real-world scenarios, patients requiring hospitalisation, particularly for acute or emergency procedures, rarely engage in price comparison at the point of admission.
Health care decisions are typically driven by urgency, physician referral, hospital network access, and insurer panel arrangements rather than publicly available percentile price ranges.
The behavioural assumption underlying the publication — that policyholders will meaningfully use statistical price data to influence hospital selection — has not been supported by empirical evidence.
Without accompanying behavioural research or decision-support tools, the likelihood of widespread consumer utilisation appears limited.
Methodological Limitations And Data Constraints
The publication is based on historical claims data; however, the study period is not disclosed. The absence of a defined reference period limits interpretability and undermines forward relevance.
In an environment characterised by persistent medical inflation — often outpacing general CPI — historical averages may quickly become outdated.
From a forward-looking actuarial and policy planning perspective, cost data lacking temporal specificity diminishes predictive reliability.
Without clarity on whether the dataset reflects 2022, 2023, or earlier treatment patterns, the applicability of the figures for 2026–2027 planning becomes questionable.
Additionally, the document employs 25th to 75th percentile ranges. While statistically defensible in reducing the influence of outliers, the resulting bill ranges are wide. For example:
Angiogram (C1), between ages 41 and 60
- Typical Bill: RM11,800
- Range: RM8,800 to RM18,700
- Average Length of Stay: 2.1 days
- Discharges: RM1,000 to RM4,999
The breadth of this range reduces practical predictability. A spread of nearly RM10,000 may not materially assist a policyholder in anticipating out-of-pocket exposure.
Furthermore, cost components are not disaggregated. It remains unclear whether figures include professional fees, consumables, implants, diagnostic investigations, or potential complications.
The absence of clinical severity adjustments further limits interpretive value. Procedures vary significantly in complexity; grouping them under a single percentile band may oversimplify real-world variability.
Accessibility And Comprehension Considerations
The publication relies on statistical terminology, including percentile ranges and discharge volumes.
Given the diversity of policyholder educational backgrounds, it is uncertain whether the majority of readers can meaningfully interpret such data without explanatory context.
For transparency initiatives to achieve behavioural impact, information must not only be available but also actionable and easily understood.
Without visual simplification, contextual explanation, or decision-support tools (e.g., scenario-based examples of out-of-pocket calculations), the document risks becoming informational rather than empowering.
Transparency in isolation does not necessarily translate into consumer leverage.
Alignment With Policyholder Priorities
Policyholders’ primary concerns typically centre on:
- Premium stability.
- Reduction in unexpected co-payments.
- Access to timely, quality health care.
- Predictability of claims approval.
The publication does not directly address these concerns. It does not explain how price benchmarking will stabilise premiums, reduce medical inflation, or improve access to care.
Nor does it clarify whether insurers will integrate these benchmarks into claims adjudication, network tiering, or cost-control mechanisms.
While a minority of policyholders may welcome price awareness, the document does not provide sufficient granularity or decision tools to enable effective hospital selection based solely on cost.
As such, its tangible benefit to the average policyholder remains limited.
Strategic Value To Assurers
From an industry perspective, the data may hold greater internal utility than public value.
Aggregated historical pricing can serve as a benchmarking tool during pricing negotiations with private health care providers. It may also support actuarial modelling, claims monitoring, and cost-containment strategies.
However, making such benchmarking data public does not inherently strengthen insurers’ negotiating positions. In fact, public dissemination could reduce strategic flexibility if providers anchor negotiations to upper percentile figures.
Therefore, while the document may support internal pricing analytics, its public release does not clearly enhance insurers’ competitive advantage or operational effectiveness.
Broader Policy Considerations
Health care transparency initiatives are most effective when integrated within a broader reform framework, such as Diagnosis-Related Group (DRG) systems, standardised billing structures, or reference pricing mechanisms.
Absent regulatory enforcement or structured payment reforms, publishing historical price ranges alone may have limited influence on systemic cost containment. Transparency is a necessary but insufficient condition for structural health care reform.
Conclusion
The publication by PIAM, MTA, and LIAM reflects a proactive attempt to improve cost transparency within Malaysia’s private health care ecosystem.
However, its direct consumer value appears limited due to wide price ranges, absence of methodological clarity, and lack of clinical severity adjustments.
As a standalone reference, it is unlikely to significantly influence patient behaviour or hospital selection at the point of care.
Its more meaningful contribution may lie in supporting insurers’ internal cost governance. Aggregated historical pricing data can strengthen assurers’ ability to benchmark treatment costs, identify pricing outliers, and negotiate more effectively with private hospitals.
When used strategically, such data may help improve price containment across commonly performed procedures.
Ultimately, premium stability remains the most critical outcome for policyholders. Sustained medical inflation directly translates into higher premiums and reduced affordability.
If transparency initiatives are integrated into broader cost-management strategies—alongside provider engagement and structured payment mechanisms—they may help moderate treatment cost escalation.
A final consideration to be answered: Was a sufficiently rigorous and objective analysis conducted before producing and publishing this document?
The credibility and long-term impact of such transparency efforts depend not only on intent but also on the customisation of publications to those intentions.
Dr Mohamed Rafick Khan is a trained physician with 12 years of experience in military medical services and over 22 years of experience in the assurance industry. He retired as the CEO of a multinational reinsurance company in 2019 and remains active as an independent international assurance industry consultant.
- This is the personal opinion of the writer or publication and does not necessarily represent the views of CodeBlue.
